Purpose: To investigate the effect of mebendazole on an in vivo solid tumor model of fibrosarcoma in
hamsters.
Methods: 24 Syrian golden hamsters of both sexes with the approximate body weight of 100g were
randomly distributed in 2 experimental and 2 control groups, with 6 animals in each group. BHK-21/C13
cells (2 x 106
) in 1 mL Glasgow Minimum Essential Medium (GMEM) were injected subcutaneously into
the back of each animal in 3 groups. The experimental groups were treated with mebendazole (460
mg/kg) via a gastric tube on a daily basis, immediately after tumor inoculation. In addition, one
experimental group received deoxycholic acid 20 mg/kg once a day. After 2 weeks, when the tumors
were approximately 1 - 2 cm in the control group, all the animals were sacrificed, and their blood
collected for laboratory analysis. The tumors were excised, their weight and diameters measured, and
the volumes calculated. The tumor samples were histopathologically assessed and the main organs
toxicologically analyzed. Images were taken and processed by an imaging software, and Ki-67-positive
cells in the tumor samples were quantified.
Results: Mebendazole diminished tumor mitosis from 18.5 ± 3.02 to 13.5 ± 3.45 (p < 0.05), vasculature
and tissue penetration, and increased necroses in tumor slices. Tumor volume and weight were
insignificantly attenuated. Toxicity was not observed.
Conclusion: Mebendazole might be an effective non-toxic agent in sarcoma therapy.  https://www.tjpr.org/admin/12389900798187/2017_16_10_19.pdf